MARCH 6, 2025

Biophytis announces its participation to the BIO-Europe Spring 2025 in Milan Biophytis is pleased to announce its participation in BIO-Europe Spring 2025, taking place in Milan, Italy, from march 17 to 19, 2025. Edouard Bieth, our Chief Business Officer, will take part in numerous meetings throughout the conference. As one of the most innovative biotechnology companies in aging, Biophytis is looking forward to connecting with industry leaders, partners and innovators to discuss the future of our lead drug candidate, BIO101 in obesity and sarcopenia. About BIO-Europe Spring In 2024, BIO-Europe brought together over 3,400 participants from 59 countries and more

Read the press release »

FEBRUARY 25, 2025

Biophytis announces its participation in the 15th International Conference on Frailty and Sarcopenia Research (ICFSR) Biophytis announces its participation in the International Conference on Frailty and Sarcopenia Research & Geroscience Task Force (ICFSR), taking place from March 12 to 14 in Toulouse. The International Conference on Frailty and Sarcopenia Research (ICFSR) is a leading annual scientific event dedicated to accelerating the development of clinical trials for frail older adults. It brings together researchers, clinicians, and industry professionals to share their experiences and advances in the prevention of frailty, disability, and dependency. All presented research undergoes a rigorous peer-review process by

Read the press release »

FEBRUARY 11, 2O25

Biophytis unveils its outlook strategies for 2025 Biophytis today unveils its strategic outlook for the year 2025. Biophytis has improved its competitive positioning and fundamentals in recent months, paving the way for accelerated execution of its strategic roadmap: Launch of the OBA clinical development program for the treatment of obesity, Strategic licensing agreement signed with Blanver, Entry into exclusive negotiations with a major Chinese pharmaceutical company, Conclusion of a co-development agreement with AskHelpU in ALS, Strengthening its financial structure. 2025 will be decisive for the company, with several major initiatives to accelerate the clinical development of BIO101 (20-Hydroxyecdysone) and its

Read the press release »

JANUARY 27, 2025

Biophytis announces its participation to the BIOMED FORUM investor conference Biophytis announces its participation in the Biomed Forum organized by All Invest Securities on February 4, 2025, in Paris. The Biomed Forum is the annual event dedicated to the healthcare sector, fostering connections between biotech or medtech companies and institutional investors. This will be an opportunity for Biophytis to engage with French and European investors, share updates on the company’s latest developments, and outline its outlook for 2025. Fullscreen Mode

Read the press release »

JANUARY 21, 2025

Biophytis and AskHelpU Sign a Co-Development Agreement in Rare Neuromuscular Diseases in China Biophytis today announces the signing of a co-development agreement with AskHelpU, the largest patient association in China for those affected by amyotrophic lateral sclerosis (ALS). Fullscreen Mode

Read the press release »

JANUARY 14, 2025

Biophytis Enters Exclusive Negotiations with a Chinese Pharmaceutical Company to License BIO101 Biophytis announces that it has entered exclusive negotiations with a leading Chinese pharmaceutical company. The purpose of these discussions is to finalize a licensing agreement to co-develop and commercialize BIO101 (20-Hydroxyecdysone) in China for its most promising and advanced indications: viral respiratory infections, sarcopenia, and obesity. The pharmaceutical company is part of an important Chinese group and stands out for its expertise in the development of innovative technologies and its ability to access a rapidly growing market. “The entry into exclusive discussions with this pharmaceutical company marks a

Read the press release »

JANUARY 8, 2025

Biophytis Announces New Cash Contribution and Debt Conversion up to €8.6 million to Finance the Obesity Program Cash contribution of €2.5 million from existing and new investors to finance the clinical development of BIO101 in obesity Conversion into equity of debt for up to €6.1 million strengthening the balance sheet Biophytis announces the completion of a refinancing transaction for a targeted total amount of €8.6 million, allowing it to solidify its financial structure with the arrival of new investors and to launch the Phase 2 OBA study in the United States. This combined transaction is structured around a cash injection

Read the press release »

JANUARY 6, 2025

Biophytis announces temporary suspension of the listing of its shares and share warrants prior to the completion of a refinancing transaction Biophytis announces today that the listing of its ordinary shares and share warrants on the Euronext Growth market, and its American Depositary Shares (ADS) on the OTC market, will be temporarily suspended as from the opening of trading. This suspension comes ahead of a refinancing transaction, details of which will be announced when trading resumes in the next few days.   Fullscreen Mode

Read the press release »

DECEMBER 24, 2024

Biophytis Will Be In San Franscico During The 2025 JP Morgan Healthcare Conference Will participate also in the following events: Sachs Conference – BioPharma Obesity Innovation Forum The BIO@JPM Week Conference Biophytis announces its participation in the inaugural BioPharma Obesity Innovation Forum (#Sachs_BOIF) on January 11, 2025, in San Francisco, as well as in the BIO@JPM Week conference during the 43rd annual JP Morgan Healthcare Conference, taking place from January 13 to 16, 2025, also in San Francisco. The JP Morgan Healthcare Conference is the largest global healthcare event, bringing together industry leaders, innovative biotech companies, technology developers, and investors

Read the press release »

DECEMBER 23, 2024

Biophytis showcased the OBA program in obesity at the 17th SCWD international congress Biophytis took part in the 17th international SCWD (Society on Sarcopenia, Cachexia & Wasting disorders) congress, a flagship event bringing together experts from around the world to share innovations on sarcopenia, cachexia and muscle wasting including weight loss induced muscle disorders. At this occasion, Rob van Maanen, Chief Medical Officer of Biophytis, presented the OBA clinical development program with BIO101 (20-hydroxyecdysone), our drug candidate to reduce GLP-1RA-induced muscle mass or function loss in patients with obesity or overweight. The clinical profile of BIO101 in obesity was presented

Read the press release »